Clinigen Secures Rights for 6 medac Therapies to Boost Patient Access to Specialist Medicines
Clinigen and medac CEOs sign their relationship expansion to improve access to medicines in APAC
LONDON, UK, 16 June 2025: Clinigen, global speciality pharmaceutical services Group, today announced a major strategic expansion with global pharmaceutical company, medac. The agreement grants Clinigen exclusive licensing and distribution rights for six of medac's key specialist oncology, haematology, and immune-mediated disease medicines across Australia, parts of Southeast Asia, and China.
In a signing event held at Clinigen's offices in London, UK, Clinigen CEO Jerome Charton and medac CEO Frank Lucaßen celebrated the broadening of their collaboration built on their successful existing relationship in Australia. Together both companies are poised to accelerate access to innovative medicines to patients in the Asia Pacific (APAC) region.
This new agreement strengthens Clinigen’s position to capitalise on the significant growth opportunities within the APAC pharmaceutical market, particularly in specialist oncology, immunology and rare diseases. By leveraging its established global distribution network, regional regulatory expertise, and proven market access strategies, Clinigen is uniquely equipped to rapidly integrate medac’s innovative portfolio. This will accelerate revenue generation from some underserved territories, supporting the company’s strategic focus on sustaining profitable growth through building relationships that drive both patient impact and shareholder value.
Jerome Charton, CEO of Clinigen, says: “Building on our successful relationship with medac in APAC is a key moment for Clinigen. We are honoured by medac's continued trust in our ability to extend the reach of these six treatments to patients in this vital region. This new agreement reinforces our shared vision to address unmet medical needs and contribute to better patient outcomes globally.”
Frank Lucaßen, CEO of medac, comments: “We have high expectations for our products in the APAC region. With the Clinigen Group we have found the ideal partner to develop and accelerate patient access in these dynamic and growing markets. We are excited to start this expanded strategic relationship in order to grant patients in the region access to our critically valuable treatments and grow our business in the region substantially.”
This press release may contain information about medicines that may not be approved in all territories. The intent of this press release is to share pertinent information with the investment community about this collaboration between Clinigen and medac and does not constitute promotion of any medicines.
Contact details
Fight or Flight on behalf of Clinigen
clinigen@fightorflight.com
Notes for Editors
About medac
At medac group, we believe that health is humanity’s most valuable resource. We never take it for granted. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a global pharmaceutical company headquartered in Germany, we offer high-quality medical products in over 90 countries worldwide. With more than 2,000 employees, we are committed to improving human health.
For more information on medac, please visit www.medac-group.com
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year.
For more information on Clinigen, please visit www.clinigen.com.